1.SummaryofthesecondreportoftheNationalCholesterolEducationProgram (NCEP)ExpertPanelondetection ,evaluationandtreat mentofhighbloodcholesterolinadults (AdultTreatmentPanel11)[].The Journal of The American Medical Association.1993
4Farmer JA,Gotto AM.Dyslipidemia and other risk factors for coronary artery disease.In Braunwald E ed: Heart disease: a textbook of cardiovasular medicine, 5th Ed. 1997, W. B. Saunders Co[].Philadelphia Medicine.
5Bischoff H. Angerbauer R,Bender J,et al.Cerivastatin: pharmacology of a novel synthetic and high active HMG-CoA reductase inhibitor[].Atherosclerosis.1997
6Bakker-Arkema RG,Davidson MH,Goldstern RJ,et al.Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia[].The Journal of The American Medical Association.1996
7Bocuzzi SJ,Bocanegra TS,Walker JF,et al.Long-tem safety and efficacy profile of simvastatin[].The American Journal of Cardiology.1991
8Du jovne CA,Chremos AN,Pool JL,et al.An expandedc lin ical evaluation of lovastatin(EXCEL)study resu lts.Ⅳadd itional perspectives on the tolerab ility of lovastatin[].The American Journal of The Medical Sciences.1991
9Hsu I,Spinler SA,Johnson NE.Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia[].Annals of Pharmacotherapy.1995
10Pedersen TR.The scandinavian simvastatin survival study group[].Randomized trial of cholesterol lowering in patients with coronary heart disease: the scandinavian simvastatin survival study(S) Lancet.1994
